The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | M | Musculo-skeletal system | |
2 | M05 | Drugs for treatment of bone diseases | |
3 | M05B | Drugs affecting bone structure and mineralization | |
4 | M05BC | Bone morphogenetic proteins |
Code | Title | |
---|---|---|
M05BC01 | Dibotermin alfa | |
M05BC02 | Eptotermin alfa |
Active Ingredient | Description | |
---|---|---|
Dibotermin alfa |
Dibotermin alfa is an osteoinductive protein that results in the induction of new bone tissue at the site of implantation. Dibotermin alfa binds to receptors on the surface of mesenchymal cells and causes cells to differentiate into cartilage- and bone-forming cells. The differentiated cells form trabecular bone as the matrix is degraded, with vascular invasion evident at the same time. |
|
Eptotermin alfa |
Eptotermin alfa, the active substance, initiates bone formation through the induction of cellular differentiation in mesenchymal cells, which are recruited to the implant site from bone marrow, periosteum and muscle. Once bound at the cell surface, the active substance induces a cascade of cellular events leading to the formation of chondroblasts and osteoblasts, which play a key role in the bone formation process. |
Title | Information Source | Document Type | |
---|---|---|---|
INDUCTOS Powder, solvent and matrix for implantation matrix | European Medicines Agency (EU) | MPI, EU: SmPC | |
OSIGRAFT Powder for suspension for implantation | European Medicines Agency (EU) | MPI, EU: SmPC |